ClinicalTrials.gov record
Completed Phase 4 Interventional Accepts healthy volunteers

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

ClinicalTrials.gov ID: NCT00137033

Public ClinicalTrials.gov record NCT00137033. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Active-Controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated With Celecoxib and Low Dose ASA Versus Naproxen and Low Dose ASA in Healthy Subjects (50-75 Years of Age)

Study identification

NCT ID
NCT00137033
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
605 participants

Conditions and interventions

Conditions

Interventions

  • ASA Drug
  • Celecoxib Drug
  • Naproxen Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 75 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2004
Primary completion
Not listed
Completion
Jun 30, 2005
Last update posted
Mar 2, 2021

2004 – 2005

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
22
Facility City State ZIP Site status
Pfizer Investigational Site Anaheim California 92801
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site Farmington Connecticut 06030-0001
Pfizer Investigational Site Waterbury Connecticut 06708
Pfizer Investigational Site Jupiter Florida 33458
Pfizer Investigational Site Miami Florida 33173
Pfizer Investigational Site Ocoee Florida 34761
Pfizer Investigational Site Pembroke Pines Florida 33024
Pfizer Investigational Site Chicago Illinois 60612-7323
Pfizer Investigational Site Newburgh Indiana 47630
Pfizer Investigational Site Davenport Iowa 52807
Pfizer Investigational Site Metairie Louisiana 70001
Pfizer Investigational Site Chevy Chase Maryland 20815
Pfizer Investigational Site New York New York 10021
Pfizer Investigational Site Raleigh North Carolina 27612
Pfizer Investigational Site Wilmington North Carolina 28401
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Duncansville Pennsylvania 16635
Pfizer Investigational Site Chattanooga Tennessee 37404
Pfizer Investigational Site Houston Texas 77074
Pfizer Investigational Site Houston Texas 77090
Pfizer Investigational Site Charlottesville Virginia 22903
Pfizer Investigational Site Chesapeake Virginia 23320-1706

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00137033, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 2, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00137033 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →